Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01)
Publication
, Conference
Chi, KN; Agarwal, N; Armstrong, AJ; Hellmis, E; Schluermann, F; Urun, Y; Xing, N; Aregay, M; Lima, J; Meulendijks, D; Azad, A
Published in: JOURNAL OF CLINICAL ONCOLOGY
2024
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Chi, K. N., Agarwal, N., Armstrong, A. J., Hellmis, E., Schluermann, F., Urun, Y., … Azad, A. (2024). Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).
Chi, Kim N., Neeraj Agarwal, Andrew J. Armstrong, Eva Hellmis, Friederike Schluermann, Yuksel Urun, Nianzeng Xing, et al. “Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.
Chi KN, Agarwal N, Armstrong AJ, Hellmis E, Schluermann F, Urun Y, et al. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01). In: JOURNAL OF CLINICAL ONCOLOGY. 2024.
Chi, Kim N., et al. “Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.
Chi KN, Agarwal N, Armstrong AJ, Hellmis E, Schluermann F, Urun Y, Xing N, Aregay M, Lima J, Meulendijks D, Azad A. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01). JOURNAL OF CLINICAL ONCOLOGY. 2024.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences